Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.85

-0.75 (-0.57%)

15:13
07/17/17
07/17
15:13
07/17/17
15:13

Technical Earnings Preview: Johnson & Johnson trending down ahead of news

The shares have been in a minor downtrend since hitting a peak of price in late June. If the news or outlook are a negative disappointment, next support of note would be at the $130 area. A breakdown below $130 would confirm a larger topping process underway. Next supports below would be at $128.25, $127.51, the $125 area, and $122.50. If the news is instead a positive surprise, a breakout above the $133 area would break the downtrend. Next resistance levels to watch as potential upside objectives would be at $135.01 and the 52-week high at $137. A move above $137 would open up a run to the $140 area.

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$131.85

-0.75 (-0.57%)

07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

BLUE

bluebird bio

$171.15

3.25 (1.94%)

20:25
12/10/17
12/10
20:25
12/10/17
20:25
Conference/Events
bluebird bio to hold a webcast »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

DIS

Disney

$104.23

-0.19 (-0.18%)

, GOOG

Alphabet

$1,037.05

6.12 (0.59%)

20:06
12/10/17
12/10
20:06
12/10/17
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

DIS

Disney

$104.23

-0.19 (-0.18%)

GOOG

Alphabet

$1,037.05

6.12 (0.59%)

GOOGL

Alphabet Class A

$1,049.38

4.81 (0.46%)

DAL

Delta Air Lines

$53.46

0.05 (0.09%)

BRK.A

Berkshire Hathaway

$294,385.33

285.33 (0.10%)

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

PXD

Pioneer Natural

$155.90

1.65 (1.07%)

AMAT

Applied Materials

$51.43

-0.87 (-1.66%)

EPD

Enterprise Products

$24.94

0.25 (1.01%)

ALLY

Ally Financial

$28.65

0.28 (0.99%)

ANTM

Anthem

$224.85

1.21 (0.54%)

USFD

US Foods

$31.00

0.38 (1.24%)

TJX

TJX

$73.88

0.04 (0.05%)

ROST

Ross Stores

$76.89

0.19 (0.25%)

MBI

MBIA

$8.08

-0.01 (-0.12%)

CVS

CVS Health

$73.09

2 (2.81%)

T

AT&T

$36.73

0.56 (1.55%)

DISH

Dish

$48.59

-0.36 (-0.74%)

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

TM

Toyota

$124.45

1.06 (0.86%)

SFTBY

SoftBank

$41.62

-0.02 (-0.05%)

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

  • 14

    Dec

  • 09

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 08

    May

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

19:25
12/10/17
12/10
19:25
12/10/17
19:25
Conference/Events
Akari Therapeutics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

BMRN

BioMarin

$81.99

1.09 (1.35%)

, ALXN

Alexion

$114.46

7.68 (7.19%)

19:11
12/10/17
12/10
19:11
12/10/17
19:11
Recommendations
BioMarin, Alexion, Celgene analyst commentary at Piper Jaffray »

Piper Jaffray remains…

BMRN

BioMarin

$81.99

1.09 (1.35%)

ALXN

Alexion

$114.46

7.68 (7.19%)

CELG

Celgene

$106.09

3.36 (3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

TWX

Time Warner

$90.71

0.34 (0.38%)

, CMCSA

Comcast

$37.95

0.06 (0.16%)

18:50
12/10/17
12/10
18:50
12/10/17
18:50
Hot Stocks
Box Office Battle: 'Coco' stays number 1 with $18.3M »

Disney (DIS) and…

TWX

Time Warner

$90.71

0.34 (0.38%)

CMCSA

Comcast

$37.95

0.06 (0.16%)

CMCSK

Comcast

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

LGF.A

Lionsgate

$31.56

-0.07 (-0.22%)

DIS

Disney

$104.23

-0.19 (-0.18%)

VIAB

Viacom

$29.29

-0.35 (-1.18%)

VIA

Viacom

$34.00

-0.25 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:38
12/10/17
12/10
18:38
12/10/17
18:38
Periodicals
Volkswagen CEO suggests ending diesel vehicles subsidies, NY Times reports »

Volkswagen CEO said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

18:35
12/10/17
12/10
18:35
12/10/17
18:35
Periodicals
Hospital giants in talks to merge, WSJ reports »

Ascension and Providence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:27
12/10/17
12/10
18:27
12/10/17
18:27
Periodicals
Volkswagen executive may ask to serve sentence in Germany, Reuters says »

Volkswagen executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGP

GGP

$23.43

0.03 (0.13%)

, BPY

Brookfield Property

$21.61

0.08 (0.37%)

18:21
12/10/17
12/10
18:21
12/10/17
18:21
Periodicals
Mall owner GGP rejects Brookfield Property buyout offer, Reuters reports »

U.S. mall owner GGP (GGP)…

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$17.96

0.01 (0.06%)

18:16
12/10/17
12/10
18:16
12/10/17
18:16
Recommendations
AtriCure analyst commentary at Piper Jaffray »

Piper Jaffray remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:11
12/10/17
12/10
18:11
12/10/17
18:11
Hot Stocks
Karyopharm presents positive phase 1/2 Eltanexor data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:09
12/10/17
12/10
18:09
12/10/17
18:09
Hot Stocks
Karyopharm presents positive Selinexor data from STOMP study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

18:05
12/10/17
12/10
18:05
12/10/17
18:05
Hot Stocks
Agios Pharmaceuticals presents updated data from DRIVE PK study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ICL

ICL

$4.03

-0.07 (-1.71%)

18:01
12/10/17
12/10
18:01
12/10/17
18:01
Hot Stocks
ICL completes sale of 50% share of IDE Technologies for $167M »

ICL announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$32.74

0.52 (1.61%)

17:52
12/10/17
12/10
17:52
12/10/17
17:52
Hot Stocks
AstraZeneca Calquence shows potential in chronic lymphocytic leukemia trials »

AstraZeneca and Acerta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

, XON

Intrexon

$13.28

0.16 (1.22%)

17:48
12/10/17
12/10
17:48
12/10/17
17:48
Hot Stocks
Ziopharm announces presentation of data from T-Cell Therapy programs »

Ziopharm Oncology (ZIOP)…

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

XON

Intrexon

$13.28

0.16 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:45
12/10/17
12/10
17:45
12/10/17
17:45
Hot Stocks
bluebird bio announces results from LentiGlobin study in Severe Sickle Cell »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:37
12/10/17
12/10
17:37
12/10/17
17:37
Hot Stocks
bluebird bio presents new data from clinical studies of LentiGlobin Gene Therapy »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

VSTM

Verastem

$4.33

0.36 (9.07%)

17:35
12/10/17
12/10
17:35
12/10/17
17:35
Hot Stocks
Verastem announces phase 3 DUO study met primary endpoint »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

CELG

Celgene

$106.09

3.36 (3.27%)

, BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:30
12/10/17
12/10
17:30
12/10/17
17:30
Hot Stocks
Celgene, bluebird bio announce updated results from CRB-401 Phase 1 study »

Celgene (CELG) and…

CELG

Celgene

$106.09

3.36 (3.27%)

BLUE

bluebird bio

$171.15

3.25 (1.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

GILD

Gilead

$74.22

1.5 (2.06%)

17:22
12/10/17
12/10
17:22
12/10/17
17:22
Hot Stocks
Kite announces long-term data from pivotal ZUMA-1 study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EPZM

Epizyme

$13.25

0.25 (1.92%)

17:18
12/10/17
12/10
17:18
12/10/17
17:18
Hot Stocks
Epizyme presents new biomarker data on Tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

17:16
12/10/17
12/10
17:16
12/10/17
17:16
Hot Stocks
Study shows Bioverativ Eloctate has potential to improve bleed protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:04
12/10/17
12/10
17:04
12/10/17
17:04
Hot Stocks
Syros Pharmaceuticals announces new preclinical data on SY-1365 »

Syros Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:00
12/10/17
12/10
17:00
12/10/17
17:00
Hot Stocks
Syros Pharmaceuticals announces initial data from phase 2 trial of SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.